Metabolism and pharmacokinetics of DIBROMODULCITOL (cas 10318-26-0)(DBD, NSC-104800) in man—II. Pharmacokinetics of DBD

Add time:08/05/2019    Source:sciencedirect.com

Dibromodulcitol (DBD), labelled with [3−H] at position C-1, was administered orally to 6 patients in a single dose of 15 mg/kg. Kinetic parameters were calculated for the effective drug (DBD + BrEpG + DAG), protein-bound hexitol moieties and free metabolites. Approximate values were estimated for the oral bioavailability of DBD. Disposal of the drug by metabolism and excretion was described by a simplified catenary model. The results indicated that 8–20% of the drug became firmly bound to macromolecules, probably by alkylation. The slow rate of alkylation in vivo (half-life 14 hr) may imply conversion of DBD into epoxides and their alkylating interaction with the target nucleofiles. The long retention of the firmly bound hexitol moieties in the body may be an indicator of the cumulative potency of DBD and must be taken into consideration by developing dosage schedules.

We also recommend Trading Suppliers and Manufacturers of DIBROMODULCITOL (cas 10318-26-0). Pls Click Website Link as below: cas 10318-26-0 suppliers

Prev:The effect of DIBROMODULCITOL (cas 10318-26-0) on resting and dividing lymphoid cells
Next:Investigation on the condensation of dialdehydes with 2-naphthol, 2-thionaphthol and dihydroxynaphthalenes)